Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.

Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.

Abstract Reconstructing the incidence of SARS-CoV-2 infection is central to understanding the state of the pandemic. Seroprevalence studies are often used to assess cumulative infections as they can identify asymptomatic infection. Since July 2020, commercial laboratories have conducted nationwide s...

Full description

Bibliographic Details
Main Authors: Bernardo García-Carreras, Matt D. T. Hitchings, Michael A. Johansson, Matthew Biggerstaff, Rachel B. Slayton, Jessica M. Healy, Justin Lessler, Talia Quandelacy, Henrik Salje, Angkana T. Huang, Derek A. T. Cummings
Format: Article
Language:English
Published: Nature Portfolio 2023-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-37944-5

Internet

https://doi.org/10.1038/s41467-023-37944-5

Similar Items